Effects of polygenic risk for major mental disorders and cross-disorder on cortical complexity.
Bipolar disorder
brain development
cortical complexity
magnetic resonance imaging (MRI)
major depressive disorder
polygenic risk
schizophrenia
surface-based morphometry
Journal
Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142
Informations de publication
Date de publication:
08 Apr 2021
08 Apr 2021
Historique:
entrez:
8
4
2021
pubmed:
9
4
2021
medline:
9
4
2021
Statut:
aheadofprint
Résumé
MRI-derived cortical folding measures are an indicator of largely genetically driven early developmental processes. However, the effects of genetic risk for major mental disorders on early brain development are not well understood. We extracted cortical complexity values from structural MRI data of 580 healthy participants using the CAT12 toolbox. Polygenic risk scores (PRS) for schizophrenia, bipolar disorder, major depression, and cross-disorder (incorporating cumulative genetic risk for depression, schizophrenia, bipolar disorder, autism spectrum disorder, and attention-deficit hyperactivity disorder) were computed and used in separate general linear models with cortical complexity as the regressand. In brain regions that showed a significant association between polygenic risk for mental disorders and cortical complexity, volume of interest (VOI)/region of interest (ROI) analyses were conducted to investigate additional changes in their volume and cortical thickness. The PRS for depression was associated with cortical complexity in the right orbitofrontal cortex (right hemisphere: p = 0.006). A subsequent VOI/ROI analysis showed no association between polygenic risk for depression and either grey matter volume or cortical thickness. We found no associations between cortical complexity and polygenic risk for either schizophrenia, bipolar disorder or psychiatric cross-disorder when correcting for multiple testing. Changes in cortical complexity associated with polygenic risk for depression might facilitate well-established volume changes in orbitofrontal cortices in depression. Despite the absence of psychopathology, changed cortical complexity that parallels polygenic risk for depression might also change reward systems, which are also structurally affected in patients with depressive syndrome.
Sections du résumé
BACKGROUND
BACKGROUND
MRI-derived cortical folding measures are an indicator of largely genetically driven early developmental processes. However, the effects of genetic risk for major mental disorders on early brain development are not well understood.
METHODS
METHODS
We extracted cortical complexity values from structural MRI data of 580 healthy participants using the CAT12 toolbox. Polygenic risk scores (PRS) for schizophrenia, bipolar disorder, major depression, and cross-disorder (incorporating cumulative genetic risk for depression, schizophrenia, bipolar disorder, autism spectrum disorder, and attention-deficit hyperactivity disorder) were computed and used in separate general linear models with cortical complexity as the regressand. In brain regions that showed a significant association between polygenic risk for mental disorders and cortical complexity, volume of interest (VOI)/region of interest (ROI) analyses were conducted to investigate additional changes in their volume and cortical thickness.
RESULTS
RESULTS
The PRS for depression was associated with cortical complexity in the right orbitofrontal cortex (right hemisphere: p = 0.006). A subsequent VOI/ROI analysis showed no association between polygenic risk for depression and either grey matter volume or cortical thickness. We found no associations between cortical complexity and polygenic risk for either schizophrenia, bipolar disorder or psychiatric cross-disorder when correcting for multiple testing.
CONCLUSIONS
CONCLUSIONS
Changes in cortical complexity associated with polygenic risk for depression might facilitate well-established volume changes in orbitofrontal cortices in depression. Despite the absence of psychopathology, changed cortical complexity that parallels polygenic risk for depression might also change reward systems, which are also structurally affected in patients with depressive syndrome.
Identifiants
pubmed: 33827729
doi: 10.1017/S0033291721001082
pii: S0033291721001082
pmc: PMC9811276
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-12Références
Eur Arch Psychiatry Clin Neurosci. 2020 Aug;270(5):533-539
pubmed: 30542819
Neuroreport. 2009 Mar 4;20(4):378-80
pubmed: 19218876
J Clin Med. 2020 Jan 25;9(2):
pubmed: 31991840
Cereb Cortex. 2019 Mar 1;29(3):952-962
pubmed: 29377989
J Affect Disord. 2008 Mar;106(3):229-40
pubmed: 17692389
J Clin Neurosci. 2019 May;63:55-61
pubmed: 30827879
Neuroimage. 2020 Mar;208:116438
pubmed: 31811902
Biol Psychiatry. 2019 Oct 1;86(7):536-544
pubmed: 31171358
Neuroreport. 2000 Dec 18;11(18):3985-8
pubmed: 11192614
Sci Rep. 2017 Mar 30;7(1):511
pubmed: 28360420
Mol Psychiatry. 2016 Mar;21(3):419-25
pubmed: 25754080
Bipolar Disord. 2018 Dec;20(8):721-732
pubmed: 29981196
Neuroscientist. 2013 Dec 20;20(4):403-417
pubmed: 24362815
Science. 2018 Jun 22;360(6395):
pubmed: 29930110
J Biomech Eng. 2010 Jul;132(7):071013
pubmed: 20590291
Brain Stimul. 2020 May - Jun;13(3):696-704
pubmed: 32289700
Psychiatry Res. 2001 Jul 1;107(1):29-43
pubmed: 11472862
Behav Brain Res. 2015;287:331-9
pubmed: 25804360
Science. 2020 Mar 20;367(6484):
pubmed: 32193296
Cereb Cortex. 2019 Mar 1;29(3):1139-1149
pubmed: 29420697
Transl Psychiatry. 2018 Apr 12;8(1):78
pubmed: 29643358
Am J Psychiatry. 2000 Oct;157(10):1552-62
pubmed: 11007705
JAMA Psychiatry. 2019 Aug 1;76(8):834-842
pubmed: 31042271
Behav Brain Funct. 2014 Nov 27;10:44
pubmed: 25431294
Schizophr Res. 2014 Feb;152(2-3):333-8
pubmed: 24365403
JAMA Psychiatry. 2015 Apr;72(4):305-15
pubmed: 25651064
Neuropsychologia. 2019 May;128:14-43
pubmed: 28951164
Am J Geriatr Psychiatry. 2013 Aug;21(8):794-802
pubmed: 23567394
Brain. 2014 Jun;137(Pt 6):1576-8
pubmed: 24771520
Am J Psychiatry. 2013 Dec;170(12):1477-86
pubmed: 23929204
Acta Psychiatr Scand. 2019 Sep;140(3):205-216
pubmed: 31265120
Nat Genet. 2012 Jul 22;44(8):955-9
pubmed: 22820512
Mol Psychiatry. 2017 Jun;22(6):900-909
pubmed: 27137745
Hum Brain Mapp. 2011 Jul;32(7):1109-24
pubmed: 20665722
Brain. 2014 Jun;137(Pt 6):1830-7
pubmed: 24740986
Trends Neurosci. 2013 May;36(5):275-84
pubmed: 23415112
Gigascience. 2015 Feb 25;4:7
pubmed: 25722852
Psychiatry Res Neuroimaging. 2017 May 30;263:44-47
pubmed: 28324693
Neuroimage Clin. 2016 Aug 24;12:492-498
pubmed: 27668175
Nat Genet. 2018 May;50(5):668-681
pubmed: 29700475
Am J Psychiatry. 2006 Feb;163(2):240-6
pubmed: 16449477
PLoS One. 2014 Jan 10;9(1):e79055
pubmed: 24427263
Mol Psychiatry. 2015 Nov;20(11):1386-96
pubmed: 25450228
Neuroimage. 2010 Nov 1;53(2):450-9
pubmed: 20630489
J Affect Disord. 2019 Jan 15;243:340-347
pubmed: 30261449
Transl Psychiatry. 2019 Feb 4;9(1):74
pubmed: 30718481
Neurosci Biobehav Rev. 2013 Feb;37(2):152-63
pubmed: 23206667
Hum Brain Mapp. 2006 Dec;27(12):994-1003
pubmed: 16671080
Biol Psychiatry. 2011 May 15;69(10):974-9
pubmed: 21257157
JAMA Psychiatry. 2018 May 1;75(5):484-492
pubmed: 29590315
Nature. 2014 Jul 24;511(7510):421-7
pubmed: 25056061
Int J Neuropsychopharmacol. 2015 Mar 30;18(8):
pubmed: 25829180
PLoS Genet. 2009 Jun;5(6):e1000529
pubmed: 19543373
Schizophr Bull. 2013 Sep;39(5):1129-38
pubmed: 23042112
Psychol Med. 2014 Oct;44(14):2927-37
pubmed: 25065859
J Neurosci. 2005 Apr 20;25(16):4146-58
pubmed: 15843618
Curr Biol. 2016 May 23;26(10):1301-5
pubmed: 27133866
Neuroimage. 2018 May 15;172:450-460
pubmed: 29410079
Nat Rev Neurosci. 2014 Apr;15(4):217-32
pubmed: 24646670
Eur Neuropsychopharmacol. 2012 Jan;22(1):1-16
pubmed: 21723712
Hum Brain Mapp. 2014 Apr;35(4):1691-9
pubmed: 23813686
PLoS Comput Biol. 2006 Mar;2(3):e22
pubmed: 16557292
Eur Neuropsychopharmacol. 2018 Oct;28(10):1115-1125
pubmed: 30119924
Arch Gen Psychiatry. 2003 Dec;60(12):1187-92
pubmed: 14662550
IEEE Trans Med Imaging. 2008 Feb;27(2):161-70
pubmed: 18334438
PLoS One. 2015 Mar 20;10(3):e0120704
pubmed: 25793287
Psychiatry Res. 2015 Jan 30;231(1):8-14
pubmed: 25480522
Neuroreport. 2019 Nov 6;30(16):1074-1080
pubmed: 31503209
Neuroimage. 2006 Jul 1;31(3):968-80
pubmed: 16530430
Nat Genet. 2018 Mar;50(3):381-389
pubmed: 29483656
Biol Psychiatry. 2013 Aug 15;74(4):280-6
pubmed: 23453289
Transl Psychiatry. 2016 Oct 18;6(10):e924
pubmed: 27754483
Nat Med. 2017 Jan;23(1):28-38
pubmed: 27918562
Stat Methods Med Res. 2003 Oct;12(5):419-46
pubmed: 14599004
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jan 10;88:287-302
pubmed: 30118825
Aust N Z J Psychiatry. 2017 Jan;51(1):32-41
pubmed: 27066817
Bipolar Disord. 2016 Feb;18(1):4-18
pubmed: 26851067
Nat Genet. 2019 May;51(5):793-803
pubmed: 31043756
Lancet. 2013 Apr 20;381(9875):1371-1379
pubmed: 23453885
Transl Psychiatry. 2014 Apr 08;4:e378
pubmed: 24713859
Nat Neurosci. 2019 Mar;22(3):343-352
pubmed: 30718901
Hum Brain Mapp. 2017 Mar;38(3):1299-1310
pubmed: 27807918
Psychol Med. 2020 Jan;50(2):187-209
pubmed: 31858931
Neuroimage. 2007 Oct 15;38(1):95-113
pubmed: 17761438
Neuropsychologia. 1971 Mar;9(1):97-113
pubmed: 5146491
Science. 2015 May 1;348(6234):499-500
pubmed: 25931539
J Neuroimaging. 2011 Apr;21(2):e134-47
pubmed: 20412393
Cereb Cortex. 1995 Jan-Feb;5(1):56-63
pubmed: 7719130
Neuroimage. 2010 Nov 15;53(3):1103-8
pubmed: 20176115
Eur Arch Psychiatry Clin Neurosci. 2019 Dec;269(8):949-962
pubmed: 30267149
Hum Brain Mapp. 2009 Nov;30(11):3719-35
pubmed: 19441021
Schizophr Bull. 2017 May 1;43(3):673-680
pubmed: 27169464
Nature. 2018 Oct;562(7726):210-216
pubmed: 30305740
Nat Neurosci. 2004 Aug;7(8):799-800
pubmed: 15338563
Nat Methods. 2013 Jan;10(1):5-6
pubmed: 23269371
Schizophr Res. 2019 Oct;212:225-228
pubmed: 31395486
Arch Gen Psychiatry. 2008 Oct;65(10):1156-65
pubmed: 18838632
Neurosci Biobehav Rev. 2016 Sep;68:47-58
pubmed: 27181908
Neuroimage. 2013 Jan 15;65:336-48
pubmed: 23041529
J Neurosci. 2018 Jan 24;38(4):767-775
pubmed: 29367287
J Psychiatry Neurosci. 2012 Nov;37(6):399-406
pubmed: 22640702
Neuroimage. 2011 Jun 1;56(3):961-73
pubmed: 21315159